MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study
- 182 Downloads
Adenoid cystic carcinoma (ACC) is among the most frequent malignancies of the salivary gland, and is notorious for its prolonged clinical course characterized by frequent recurrences often years after initial treatment. No molecular marker has been shown to have independent prognostic value in ACC, including characteristic gene fusions involving MYB, MYBL1, and NFIB. MicroRNA has been shown to be associated with clinical outcome in numerous malignancies, including one study of ACC, warranting further validation of this class of markers in this disease. Here, we investigate the prognostic value of microRNA in two ACC cohorts: a training cohort (n = 64) and a validation cohort (n = 120) with microarray and qPCR. In the training cohort, multivariate analysis of microarray data found high expression of hsa-miR-6835-3p to be associated with reduced recurrence-free survival (RFS) (p = 0.016). Measuring the highest ranking microRNAs identified in survival analysis in the same cohort, qPCR identified high expression of hsa-miR-4676 to be associated with reduced overall survival (OS) and high expression of hsa-mir-1180 to be associated with improved RFS. This was not confirmed in the validation cohort, in which qPCR identified high expression of hsa-mir-21, hsa-mir-181a-2, and hsa-mir-152 to be associated with reduced OS and high expression of hsa-miR-374c to be associated with improved RFS. Interestingly, two distinct subsets of ACC separated in microRNA expression irrespective of gene fusion status, but without significant difference in outcome. Collectively, qPCR identified several microRNAs associated with OS and RFS, and different subsets of ACC separated according to microRNA expression, suggestive of ACC being a heterogeneous group of malignancies in its microRNA profile.
KeywordsAdenoid cystic carcinoma Salivary gland microRNA Prognosis MYB MYBL1
We wish to thank Katarina Larsen and Lene Pedersen for valuable assistance with miRNA extraction.
SA was supported by Einar Willumsen Foundation, Merchant Kristjan Kjær and wife Margrethe Kjær’s Foundation, The Danielsen Foundation, Else and Mogens Wedell-Wedellsborg’s Foundation, Region Zealand’s Research Fund, Hans Skouby and wife Emma Skouby’s Foundation, and the A.P. Møller Foundation for the Advancement of Medical Research.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 1.Bjørndal K, Krogdahl A, Therkildsen MH, Charabi B, Kristensen CA, Andersen E, Schytte S, Primdahl H, Johansen J, Pedersen HB, Andersen LJ, Godballe C (2015) Salivary adenoid cystic carcinoma in Denmark 1990–2005: Outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish head and neck Cancer group (DAHANCA). Oral Oncol 51:1138–1142. https://doi.org/10.1016/j.oraloncology.2015.10.002 CrossRefPubMedGoogle Scholar
- 4.Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR, Phillips TL, Fu KK, Eisele DW (2006) Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: Prognostic features of recurrence. Int J Radiat Oncol Biol Phys 66:152–159. https://doi.org/10.1016/j.ijrobp.2006.04.014 CrossRefPubMedGoogle Scholar
- 8.Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106:18740–18744. https://doi.org/10.1073/pnas.0909114106 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal A, Caulin C, El-Naggar AK (2016) Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res 22:725–733. https://doi.org/10.1158/1078-0432.CCR-15-2867-T CrossRefPubMedGoogle Scholar
- 11.Liu B, Mitani Y, Rao X, Zafereo M, Zhang J, Zhang J, Futreal A, Lozano G, El-Naggar AK (2017) Spatio-temporal genomic heterogeneity, phylogeny, and metastatic evolution in salivary adenoid cystic carcinoma. JNCI J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx033
- 12.Sajed DP, Faquin WC, Carey C, Severson EA, Afrogheh A, Johnson C, Blacklow SC, Chau NG, Lin DT, Krane JF, Jo VY, Garcia JJ, Scholl LM, Aster JC (2017) Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is associated with worse outcome in adenoid cystic carcinoma. Am J Surg Pathol 41:1473–1482. https://doi.org/10.1097/PAS.0000000000000945 CrossRefPubMedGoogle Scholar
- 13.Ferrarotto R, Mitani Y, Diao L et al (2017) Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol 35:352–360. https://doi.org/10.1200/JCO.2016.67.5264 CrossRefPubMedGoogle Scholar
- 14.Frerich CA, Brayer KJ, Painter BM, Kang H, Mitani Y, El-naggar AK, Ness SA (2017) Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget 9:7341–7358. https://doi.org/10.18632/oncotarget.23641 PubMedPubMedCentralCrossRefGoogle Scholar
- 21.Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM, El-Naggar AK (2013) MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. PLoS One 8:e66778. https://doi.org/10.1371/journal.pone.0066778 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J (2011) Biospeciment reporting for improved study quality (BRISQ). J Proteome Res 10:3429–3438. https://doi.org/10.1021/pr200021n CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homøe P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen H, Andersen LJ, Godballe C (2011) Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish head and neck Cancer group (DAHANCA). Oral Oncol 47:677–682. https://doi.org/10.1016/j.oraloncology.2011.04.020 CrossRefPubMedGoogle Scholar
- 26.Stenman G, Licitra L, Said-Al-Naief N, van Zante A, Yarborough W (2017) Adenoid cystic carcinoma. In: El-Naggar A, Chan J, Grandis J, Takata T, Slootweg P (eds) World Health Organization classification of tumours. IARC Press, Lyon, 164–165Google Scholar
- 28.Andreasen S, Bishop JA, Hansen TV, Westra WH, Bilde A, von Buchwald C, Kiss K (2017) Human Papillomavirus-related Carcinoma with Adenoid Cystic-like Features of the Sinonasal Tract: Clinical and Morphological Characterization of 6 New Cases. Histopathology 70:880–888. https://doi.org/10.1111/his.13162 CrossRefPubMedGoogle Scholar
- 30.Andreasen S, Melchior LC, Kiss K, Bishop JA, Høgdall E, Grauslund M, Wessel I, Homøe P, Agander TK (2018) The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. Cancer Cytopathol 126:275–281. https://doi.org/10.1002/cncy.21959 CrossRefPubMedGoogle Scholar
- 33.Howe K (2017) Extraction of miRNAs from formalin-fixed paraffin-embedded (FFPE) tissues. Methods Mol Biol. https://doi.org/10.1007/978-1-4939-6524-3_3
- 35.Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599–608. https://doi.org/10.1097/PAS.0b013e3181d9efcc PubMedCrossRefGoogle Scholar
- 37.Bass BP, Engel KB, Greytak SR, Moore HM (2014) A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue. How well do you know your FFPE specimen? Arch Pathol Lab Med 138:1520–1530. https://doi.org/10.5858/arpa.2013-0691-RA CrossRefPubMedGoogle Scholar
- 38.Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM (2012) Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 107:684–894. https://doi.org/10.1038/bjc.2012.294 CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403. https://doi.org/10.1002/ijc.24715 PubMedCrossRefGoogle Scholar
- 42.Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436. https://doi.org/10.1001/jama.299.4.425 PubMedPubMedCentralCrossRefGoogle Scholar
- 43.Amit M, Binenbaum Y, Trejo–Leider L, Sharma K, Ramer N, Ramer I, Agbetoba A, Miles B, Xang X, Lei D, Bjørndal K, Godballe C, Mücke T, Wolff KD, Eckardt AM, Copelli C, Sesenna E, Palmer F, Ganly I, Patel S, Gil Z (2015) International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck 37:1038–1045. https://doi.org/10.1002/hed.23710 CrossRefPubMedGoogle Scholar
- 44.Barrett AW, Speight PM (2009) Perineural invasion in adenoid cystic carcinoma of the salivary glands: a valid prognostic indicator? Oral Oncol 45:936–940. https://doi.org/10.1016/j.oraloncology.2009.07.001 CrossRefPubMedGoogle Scholar
- 45.Ma W, Kang Y, Ning L, Tan J, Wang H, Ying Y (2017) Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Exp Ther Med 14:2853–2862. https://doi.org/10.3892/etm.2017.4847 CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Andersson MK, Afshari MK, Andre Y, Wick MJ, Stenman G (2017) Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx017